Sofiya Portuhay
Expertise:
Sofiya joined the Value & Evidence division of EVERSANA in 2021 as a Research Assistant.
At EVERSANA, Sofiya has supported systematic and targeted literature reviews across various disease areas, such as various cancers, pulmonary arterial hypertension and angioedema, etc. She also has experience in feasibility assessments and indirect treatment comparisons.
Prior to joining the team, Sofiya worked as a Medical Transcriptionist and Research Assistant. She focused on autoimmune disorders, allergic conditions, and their impact on mental health.
Sofiya holds an Honours Bachelor of Science in Biochemistry from McMaster University. She completed her undergraduate thesis project at the Thrombosis and Atherosclerosis Research Institute, focusing on the effects of gene manipulation on left ventricular plaque development, as well as the regenerative role of myofibroblasts post myocardial infarction.
She is currently pursuing her MSc in Health Systems Research at the University of Toronto.
Articles by Sofiya Portuhay
Expanding the Evidence: Real-World Insights into CDK4/6i Use in Elderly and BIPOC Patients with Metastatic Breast Cancer
Randomized controlled trials have long served as the foundation for establishing treatment efficacy, but they often fall short in representing the full diversity of patients seen in clinical practice. This is especially true in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced/metastatic breast cancer (a/mBC), where elderly populations and individuals who identify as black, […]
Beyond Clinical Trials: Real-World Evidence Illuminates the Value of First-Line CDK4/6i in Metastatic Breast Cancer
While randomized controlled trials (RCTs) have been instrumental in establishing new standards of care, a comprehensive understanding of treatment effectiveness requires insights from real-world evidence (RWE). This is particularly true in the evolving landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (A/MBC), the most commonly diagnosed subtype globally. The introduction […]